Treatment of primary ovarian cancer: A systematic review;Primærbehandling av ovarialcancer

Tidsskrift for den Norske Laegeforening

Volumn 125, Issue 3, 2005, Pages 278-281

  Lyngstadaas, Anita ^a,c   Ekanger, Roald ^b   Hagen, Bjørn ^b   Himmelmann, Anna ^b   Iversen, Ole Erik ^b   Iversen, Torbjørn ^b   Nordal, Randi ^b   Norheim, Ole Frithjof ^b   Onsrud, Mathias ^b   Tretli, Steinar ^b   Tropé, Claes ^b  

^a Medlemmer av SMMs Ekspertgruppe ^*  (Norway)

^b SINTEF   (Norway)

^c Nasjonalt Kunnskapssenter H   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOXORUBICIN; MELPHALAN; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; HUMAN; OVARY CANCER; POSTOPERATIVE CARE; QUALITY CONTROL; REVIEW; SCIENTIFIC LITERATURE; SURVIVAL RATE; SYSTEMATIC REVIEW; VALIDATION PROCESS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; FEMALE; OVARY TUMOR; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 14744281701     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Cancer in Norway 1999. Kreftregisteret, Oslo 2002. http://www. kreftregisteret.no (10.6.2003).
2. Primær behandling av ovarialcancer. SMM rapport nr. 5/2003. Oslo: Senter for medisinsk metodevurdering, 2003. http://www.sintef.no/smm (28.4.2004).
3. Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer - adjuvant chemotherapy in ovarian cancer. J Natl Cancer Inst 2003; 95: 113-24.
4. International collaborative ovarian neoplasm trial 1: a randomised trial of adjuvant chemotherapy in women with early-stage ovarian cancer. International Collaborative Ovarian Neoplasm (ICON1) Collaborators. J Natl Cancer Inst 2003; 95: 125-32.
5. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105-12.
6. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20: 1248-59.
7. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001; 91: 2329-34.
8. Kayikcioglu F, Kose MF, Boran N et al. Neoadjuvant chemotherapy and primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11: 466-70.
9. Kuhn W, Rutke S, Spathe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage MIC ovarian carcinoma. Cancer 2001; 92: 2585-91.
10. Phase III randomized study of neoadjuvant chemotherapy followed by interval debulking surgery versus upfront cytoreductive surgery followed by chemotherapy with or without interval debulking surgery in patients with stage IIIc or IV ovarian epithelial, peritoneal, or fallopian tube cancer. Protocol EORTC-55971. http://www.cancer.gov (11.6.2003).
11. A randomised trial of interval debulking surgery in epithelial ovarian cancer suboptimally debulked at primary surgery. MRC Protocol ISRCTN84121653. http://www.controlled-trials.com (11.6.2003).
12. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106-15.
13. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICONS randomised trial. Lancet 2002; 360: 505-15.
14. Kaye SB, Scottish Gynaecological Cancer Trials Group. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer 2001; 11 (suppl 1): 31-3.